198 related articles for article (PubMed ID: 32592916)
1. Intralipid therapy for unexplained recurrent miscarriage and implantation failure: Case-series and literature review.
Plaçais L; Kolanska K; Kraiem YB; Cohen J; Suner L; Bornes M; Sedille L; Rosefort A; D'Argent EM; Selleret L; Abisror N; Johanet C; Buffet NC; Darai E; Antoine JM; Fain O; Kayem G; Mekinian A
Eur J Obstet Gynecol Reprod Biol; 2020 Sep; 252():100-104. PubMed ID: 32592916
[TBL] [Abstract][Full Text] [Related]
2. Preimplantation genetic testing for aneuploidy: a comparison of live birth rates in patients with recurrent pregnancy loss due to embryonic aneuploidy or recurrent implantation failure.
Sato T; Sugiura-Ogasawara M; Ozawa F; Yamamoto T; Kato T; Kurahashi H; Kuroda T; Aoyama N; Kato K; Kobayashi R; Fukuda A; Utsunomiya T; Kuwahara A; Saito H; Takeshita T; Irahara M
Hum Reprod; 2019 Dec; 34(12):2340-2348. PubMed ID: 31811307
[TBL] [Abstract][Full Text] [Related]
3. Time to conception and time to live birth in women with unexplained recurrent miscarriage.
Kaandorp SP; van Mens TE; Middeldorp S; Hutten BA; Hof MH; van der Post JA; van der Veen F; Goddijn M
Hum Reprod; 2014 Jun; 29(6):1146-52. PubMed ID: 24682612
[TBL] [Abstract][Full Text] [Related]
4. Non-visualized pregnancy losses are prognostically important for unexplained recurrent miscarriage.
Kolte AM; van Oppenraaij RH; Quenby S; Farquharson RG; Stephenson M; Goddijn M; Christiansen OB;
Hum Reprod; 2014 May; 29(5):931-7. PubMed ID: 24603132
[TBL] [Abstract][Full Text] [Related]
5. Unexplained recurrent implantation failures: Predictive factors of pregnancy and therapeutic management from a French multicentre study.
Kolanska K; Bendifallah S; Cohen J; Placais L; Selleret L; Johanet C; Suner L; Delhommeau F; Chabbert-Buffet N; Darai E; Antoine JM; Kayem G; Fain O; Mathieu d'Argent E; Mekinian A
J Reprod Immunol; 2021 Jun; 145():103313. PubMed ID: 33774529
[TBL] [Abstract][Full Text] [Related]
6. Unexplained Recurrent Miscarriage and Recurrent Implantation Failure: Is There a Place for Immunomodulation?
Mekinian A; Cohen J; Alijotas-Reig J; Carbillon L; Nicaise-Roland P; Kayem G; Daraï E; Fain O; Bornes M
Am J Reprod Immunol; 2016 Jul; 76(1):8-28. PubMed ID: 26847715
[TBL] [Abstract][Full Text] [Related]
7. Effect of empiric intravenous intralipid therapy on pregnancy outcome in women with unexplained recurrent implantation failure undergoing intracytoplasmic sperm injection-embryo transfer cycle: a randomized controlled trial.
Al-Zebeidi J; Agdi M; Lary S; Al-Obaid S; Salim G; Al-Jaroudi D
Gynecol Endocrinol; 2020 Feb; 36(2):131-134. PubMed ID: 31220957
[TBL] [Abstract][Full Text] [Related]
8. Intralipid therapy and adverse reproductive outcome: is there any evidence?
Kumar P; Marron K; Harrity C
Reprod Fertil; 2021 Jul; 2(3):173-186. PubMed ID: 35118388
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy to improve pregnancy outcome in women with abnormal natural killer cell levels/activity and recurrent miscarriage or implantation failure: A systematic review and meta-analysis.
Woon EV; Day A; Bracewell-Milnes T; Male V; Johnson M
J Reprod Immunol; 2020 Nov; 142():103189. PubMed ID: 32889304
[TBL] [Abstract][Full Text] [Related]
10. Does immunotherapy for treatment of reproductive failure enhance live births?
Coulam CB; Acacio B
Am J Reprod Immunol; 2012 Apr; 67(4):296-304. PubMed ID: 22340745
[TBL] [Abstract][Full Text] [Related]
11. The effect of administration of intravenous intralipid on pregnancy outcomes in women with implantation failure after IVF/ICSI with non-donor oocytes: A randomised controlled trial.
Singh N; Davis AA; Kumar S; Kriplani A
Eur J Obstet Gynecol Reprod Biol; 2019 Sep; 240():45-51. PubMed ID: 31228675
[TBL] [Abstract][Full Text] [Related]
12. Maternal KIR haplotype influences live birth rate after double embryo transfer in IVF cycles in patients with recurrent miscarriages and implantation failure.
Alecsandru D; Garrido N; Vicario JL; Barrio A; Aparicio P; Requena A; García-Velasco JA
Hum Reprod; 2014 Dec; 29(12):2637-43. PubMed ID: 25316448
[TBL] [Abstract][Full Text] [Related]
13. Intralipid treatment for women with reproductive failures.
Coulam CB
Am J Reprod Immunol; 2021 Apr; 85(4):e13290. PubMed ID: 32567756
[TBL] [Abstract][Full Text] [Related]
14. Intravenous intralipid therapy is not beneficial in having a live delivery in women aged 40-42 years with a previous history of miscarriage or failure to conceive despite embryo transfer undergoing in vitro fertilization-embryo transfer.
Check JH; Check DL
Clin Exp Obstet Gynecol; 2016; 43(1):14-5. PubMed ID: 27048011
[TBL] [Abstract][Full Text] [Related]
15. What is the prognosis for a live birth after unexplained recurrent implantation failure following IVF/ICSI?
Koot YEM; Hviid Saxtorph M; Goddijn M; de Bever S; Eijkemans MJC; Wely MV; van der Veen F; Fauser BCJM; Macklon NS
Hum Reprod; 2019 Oct; 34(10):2044-2052. PubMed ID: 31621857
[TBL] [Abstract][Full Text] [Related]
16. Intralipid supplementation in women with recurrent spontaneous abortion and elevated levels of natural killer cells.
Dakhly DM; Bayoumi YA; Sharkawy M; Gad Allah SH; Hassan MA; Gouda HM; Hashem AT; Hatem DL; Ahmed MF; El-Khayat W
Int J Gynaecol Obstet; 2016 Dec; 135(3):324-327. PubMed ID: 27614789
[TBL] [Abstract][Full Text] [Related]
17. Gestational age of pregnancy loss in women with unexplained recurrent miscarriage.
Ticconi C; Giuliani E; Sorge R; Patrizi L; Piccione E; Pietropolli A
J Obstet Gynaecol Res; 2016 Mar; 42(3):239-45. PubMed ID: 26663368
[TBL] [Abstract][Full Text] [Related]
18. Aetiology of recurrent miscarriage and the role of adjuvant treatment in its management: a retrospective cohort review.
Dobson SJA; Jayaprakasan KM
J Obstet Gynaecol; 2018 Oct; 38(7):967-974. PubMed ID: 29557233
[TBL] [Abstract][Full Text] [Related]
19. A comparison of transcriptomic profiles in endometrium during window of implantation between women with unexplained recurrent implantation failure and recurrent miscarriage.
Huang J; Qin H; Yang Y; Chen X; Zhang J; Laird S; Wang CC; Chan TF; Li TC
Reproduction; 2017 Jun; 153(6):749-758. PubMed ID: 28283674
[TBL] [Abstract][Full Text] [Related]
20. Intralipid® may represent a new hope for patients with reproductive failures and simultaneously an over-immune endometrial activation.
Lédée N; Vasseur C; Petitbarat M; Chevrier L; Vezmar K; Dray G; Chenière S; Lobersztajn A; Vitoux D; Cassuto GN; Chaouat G
J Reprod Immunol; 2018 Nov; 130():18-22. PubMed ID: 30286362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
